$LGVN

Longeveron Inc. (LGVN) shares fell 60% after its stem cell therapy failed to meet the primary goal in a late-stage trial for a rare pediatric heart condition. The company plans to cut costs and explore strategic alternatives. It had $10.1M in cash at the end of June, with operations funded into Q4. The FDA had previously indicated that the trial's primary endpoint alone would not support approval.

Longeveron Inc. (LGVN) reported that its Phase 2b trial for a heart treatment missed the primary efficacy endpoint. The company is reviewing strategic options, engaging an investment bank, and implementing cash-conservation measures. LGVN had $10.1M in cash as of June 30, with operations expected to be funded into Q4 2026. The company's aging-related frailty program and intellectual property may retain value for potential partners.

Longeveron Inc (LGVN) shares fell 59% after its stem cell therapy failed to meet the main goal in a mid-stage study for a rare infant heart defect. The company now plans to review options to protect shareholders, with $10M in cash to fund operations into Q4. The FDA had previously indicated the study's main measure was inadequate for approval.

Longeveron (LGVN) reported a Q2 2026 net loss of $6.1M, a 22% increase due to higher expenses. Revenue was $0.3M, down 10% YoY. Cash reserves of $10.1M are expected to last until Q4 2026. The company anticipates ELPIS II trial results in September 2026 and is seeking partnerships for its stem cell therapy, laromestrocel. It also received a $1M XPRIZE award and aims for potential $81M grand prize.

Longeveron Inc. (LGVN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Longeveron Appoints Nirav Jhaveri as Chief Financial Officer ● Mr. Jhaveri has over 25 years of experience in capital markets, corporate finance, business development and investor relations, including more than 15 years in the biotech sector MIAMI, Fla., August 19, 2

Longeveron Inc. (LGVN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Longeveron Announces 2026 Second Quarter Financial Results and Provides Business Update ● On track for September 2026 top-line results from Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for hypoplastic left heart syndrom

Longeveron Inc. (LGVN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 ea029798701ex10-1.htm REVISED LETTER AGREEMENT, DATED JULY 8, 2026 Exhibit 10.1 July 8, 2026 Dear Steve: This revised letter agreement (this “ Agreement ”) sets forth the terms and conditions of your (referred to as “you” or “your” or “executive”) employment with Longev

Longeveron Inc. (LGVN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001721484 0001721484 2026-07-08 2026-07-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Repor

Longeveron Inc. (LGVN) said CFO Lisa Locklear will step down, and Marie Washburn will become CFO effective July 13. Longeveron is preparing for Phase 2b Phase 2b laromestrocel results for Hypoplastic Left Heart Syndrome in Q3 2026. LGVN closed at $0.6495, down 5.94%, and fell further in after-hours.

Longeveron Inc. (NASDAQ: LGVN) appointed Marie Washburn as Senior VP and CFO effective July 13, 2026, replacing Lisa Locklear. The company said Washburn has 20+ years in pharma/biotech finance. Longeveron’s Phase 2b trial of laromestrocel in HLHS is expected to report top-line results in Q3 2026.